Imagine a relay race instead of a single appointment once hereditary genetic testing wraps up, with each handoff guiding the next decision. Results, counseling, medical planning, family conversations, and legal questions hand the baton off across weeks and months, with each leg shaped by which of three result categories your report lands in. Laboratories sort findings into positive, negative, or variant of uncertain significance (VUS), and that first classification drives every step that follows.
This walkthrough covers the seven stages that follow a hereditary test, the decisions that actually matter at each one, and the questions worth asking your genetics clinic, your relatives, and your insurer along the way.
Receiving Your Results and Understanding the Three Possible Outcomes
Three result categories shape everything downstream. A positive result confirms a pathogenic variant, meaning a gene change known to raise disease risk has been identified in your sample. A negative result shows no pathogenic variant in the genes the lab analyzed, though it never rules out every hereditary cause. A variant of uncertain significance (VUS) means the lab spotted a gene change but cannot yet tell whether it raises risk, is harmless, or sits somewhere in between.
Positive, Negative, and VUS Explained
A positive finding usually names the specific gene affected and references the condition tied to it, such as Lynch syndrome or hereditary breast and ovarian cancer syndrome linked to BRCA1 or BRCA2. A negative report is only as complete as the panel ordered, because a 12-gene panel cannot rule out variants in genes the lab never sequenced.
A VUS sits in limbo by design, reported because the lab is obligated to share what it sees, then flagged as uninterpretable so it does not drive medical decisions on its own.
Turnaround Time and Incidental Findings
Most clinical labs return results in 2 to 6 weeks, though family-based testing can stretch the timeline when a relative’s sample runs alongside yours. Incidental findings sometimes arrive too, meaning the lab stumbled onto a variant relevant to a different condition than the one you originally tested for.
The American College of Medical Genetics (ACMG) maintains a list of genes labs are encouraged to scrutinize for secondary findings, so even a focused breast cancer panel can surface an unrelated cardiac risk.
A secondary cardiac finding can feel jarring, so a counselor helps you weigh what it actually changes about your care.
Working With a Genetic Counselor to Interpret What Your Results Mean
A genetic counselor translates laboratory shorthand into a risk number you can actually use. The session usually lasts 45 to 90 minutes and covers what the report says, what it does not say, and how the finding fits your family tree. Counselors build a pedigree, a family-history diagram that traces who had what, when, and at what age, then fold your personal history into published evidence to produce a risk estimate grounded in your specifics.
Reading a Variant of Uncertain Significance
A VUS is not a diagnosis, and acting on it as one ranks among the most common missteps after hereditary genetic testing. Counselors will usually recommend treating a VUS as inconclusive, with no enhanced screening, no preventive surgery, and no family cascade testing, until evidence accumulates. Reclassification happens: labs review VUS records periodically, and a meaningful share of findings move to benign or pathogenic over several years, which is why holding onto your report matters.
How Reclassification Changes Interpretation
Variant reclassification is not theoretical. Studies of large hereditary cancer panels show roughly 7% to 15% of VUS results get reclassified within five years, most often reclassified as benign once more carriers are identified and studied. A small minority move the other direction, from uncertain to pathogenic, which is the update that actually changes medical management.
Counseling sessions typically end with a recommendation to check back with the lab or a clinician every 12 to 24 months, and many labs now send automatic reclassification notices if you opted in.
Building a Medical Management Plan Based on Your Findings
A positive finding turns into a written plan, usually coordinated by a genetics clinic and shared with whichever specialists match the result. For hereditary breast and ovarian cancer syndrome linked to BRCA1 or BRCA2, that often means earlier and more frequent breast MRI, mammography, and a conversation about risk-reducing surgery once childbearing is complete. For Lynch syndrome, the plan usually includes colonoscopies every 1 to 2 years, gynecologic screening, and sometimes daily aspirin under a clinician’s guidance.
Surveillance, Preventive Surgery, and Risk-Reducing Options
The National Comprehensive Cancer Network (NCCN) publishes guidelines that translate specific gene variants into recommended surveillance intervals, imaging modalities, and surgical thresholds. Those recommendations get updated annually, so a plan written in 2019 may look different from one written today. Medication options sometimes enter the picture too, including risk-reducing agents for certain breast cancer risk profiles, though any medication decision belongs in a conversation with the prescribing clinician who knows your full history.
| Finding Category | Typical Surveillance | Specialists Often Involved |
|---|---|---|
| BRCA1/BRCA2 pathogenic variant | Annual breast MRI and mammogram, consideration of risk-reducing salpingo-oophorectomy | Breast specialist, gynecologic oncologist, plastic surgeon |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2) | Colonoscopy every 1 to 2 years, endometrial and ovarian screening | Gastroenterologist, gynecologic oncologist |
| Hereditary cardiomyopathy variant | Echocardiogram every 1 to 3 years, ECG, cardiac MRI as indicated | Cardiologist, electrophysiologist |
| Negative result with strong family history | Continue risk-based screening per family history, consider expanded panel | Geneticist, primary care clinician |
Why a Multidisciplinary Team Matters
One specialist rarely owns the whole picture after a hereditary result lands. A positive finding in a cardiology gene, for instance, might pull in a cardiologist, an electrophysiologist, and a genetics clinician simultaneously, each weighing in on surveillance, activity restrictions, and family screening. Reproductive medicine enters the conversation for people of childbearing age, since preimplantation genetic testing is now a real option for couples who want to reduce the chance of passing a known pathogenic variant to a child.
A multidisciplinary approach keeps recommendations consistent across providers and closes the gaps that appear when one clinician assumes another has handled a topic.
Once that multidisciplinary plan is in place, the conversation naturally shifts to relatives who may share the same risk.
Hold off on scheduling a battery of screenings the day your results arrive. A genetic counselor helps you prioritize which steps belong in the next month versus the next year, and that sequencing often matters as much as the screenings themselves.
Communicating With Family Members and Considering Cascade Testing
First-degree relatives each face a 50% chance of carrying the same autosomal dominant variant identified in your report. That statistical reality is why cascade testing, the process of offering targeted genetic testing to at-risk relatives, is recommended once a pathogenic variant is confirmed. The conversation that opens the door to cascade testing often falls on the person who tested first, and that conversation is rarely the easiest one of the week.
Starting the Conversation With Relatives
Genetic counselors often prepare a one-page family letter you can send or email, summarizing the result, the gene involved, and the recommendation to consider a targeted test for the specific variant. The letter typically includes a lab order form so relatives can pursue testing without redoing the full panel. Timing matters: relatives are more likely to follow through when the conversation happens during a calm window rather than during a cancer diagnosis or family crisis.
Some families gather the conversation into a single phone call or video meeting; others share one-on-one, matching the format to the relationship.
When Results Reveal Unexpected Family Information
Occasionally, a hereditary result surfaces information nobody anticipated. A negative finding when a parent is positive can be clinically clarifying but emotionally loaded, since it tells one sibling they carry no risk while another does. More rarely, genetic findings expose misattributed parentage or undisclosed adoptions, moments when a clean clinical result collides with a complex family truth.
Genetic counselors are trained to flag these possibilities before testing begins, so most families enter the process already aware that biology and family lore sometimes diverge.
Understanding Your Legal Protections and Where Gaps Remain
Federal law in the United States offers partial protection through the Genetic Information Nondiscrimination Act (GINA), signed in 2008. GINA bars health insurers from using genetic information to deny coverage, raise premiums, or set eligibility, and it bars most employers from making hiring, firing, or promotion decisions based on genetic results. Those protections are real, but they stop short of the full picture.
What GINA Covers and What It Does Not
Life insurance, disability insurance, and long-term care insurance fall outside GINA. Insurers in those markets can ask about genetic results, request records, and use the information in underwriting decisions. The U.S. Preventive Services Task Force has separately flagged that gaps in life and disability coverage remain a practical concern for people considering predictive testing, which is why some individuals pursue testing under a different name or pay out of pocket to keep results out of insurance databases.
State laws sometimes fill the federal gaps, and a handful of states prohibit genetic discrimination in life, disability, or long-term care insurance markets. State rules vary widely and change frequently, so checking the law in your state before sharing results with any insurer is worth the call.
Even with strong legal protections, acting on results carelessly can still create practical headaches worth sidestepping.
Heads up: GINA covers health insurance and employment. It does not protect life, disability, or long-term care underwriting, and those markets can request your results during the application process.
Avoiding Common Pitfalls When Acting on Genetic Test Results
Most missteps after hereditary genetic testing fall into a handful of predictable categories, and most are avoidable with a clear head and a few guiding questions. The pitfalls are not abstract risks; they are decisions people make in real clinics every week, sometimes with irreversible consequences.
Treating a VUS as a Diagnosis
The single most common error is acting on a VUS as though it were a positive finding, scheduling prophylactic surgeries, restricting family members, or paying for cascade screening on a gene change the lab has flagged as uncertain. Because VUS reclassification takes years and often trends toward benign, premature action can produce surgeries or screenings that turn out to have been unnecessary.
Holding the line on a VUS, and revisiting the result every 12 to 24 months, is the safer path until evidence clarifies the variant’s meaning.
Skipping Counseling to Save Time or Cost
Direct-to-consumer tests screen a small subset of variants and do not offer clinical-grade interpretation. Going from a recreational finding straight to surgery without clinical confirmation is a path that has produced documented harm.
Even within clinical testing, skipping the counseling step to save an appointment fee often backfires, because the lab report assumes a reader who knows how to weigh a VUS, a benign polymorphism, and a pathogenic variant, three categories that look similar on paper but mean very different things.
Forgetting to Revisit Results Over Time
Guidelines evolve, panels expand, and variant classifications change. A report from five years ago may list a VUS that has since been downgraded to benign, or may omit a gene that current guidelines recommend screening. A practical habit is to schedule a 15-minute check-in with your genetics clinic every two to three years, especially if your family history has changed or if new cancers have appeared in relatives.
Laboratories also recontact patients when reclassification occurs, but only if you opted into recontact communications at the time of testing.
- Confirm any VUS interpretation: Have a clinician weigh in before you change screening or surgical plans.
- Verify clinical-grade testing: Confirm a clinical result before acting on a direct-to-consumer finding.
- Check state insurance rules: Review protections on life and disability insurance before sharing results with any insurer.
- Store the lab report: Keep the original report accessible; reclassification notices often arrive years later.
- Opt into recontact: Ask your genetics clinic to notify you if the lab reclassifies a variant you carry.
Key Takeaway
Hereditary genetic testing does not end with a result. The months afterward turn the report into a medical plan, a family conversation, a legal decision, and a long-term relationship with a genetics team that revisits your variant list as evidence accumulates. The single most important habit is staying in touch with your genetics clinic long after the initial counseling session, because variant science moves faster than any single report can keep up with.
FAQ
What should I expect after completing hereditary genetic testing?
Expect a relay rather than a single appointment: results in 2 to 6 weeks, a 45 to 90 minute genetic counseling session, a written medical management plan, conversations with first-degree relatives about cascade testing, and an annual or biennial check-in to catch reclassification updates and guideline changes.
How long does it take to get hereditary genetic test results?
Most clinical labs return hereditary results in 2 to 6 weeks. Family-based testing, where a relative’s sample runs alongside yours, can add time, and direct-to-consumer results typically arrive faster but lack clinical-grade interpretation.
Who interprets my genetic test results and explains what they mean?
A genetic counselor interprets your report in a 45 to 90 minute session, translates the laboratory language into a personal risk estimate, and builds a pedigree that fits the finding to your family history. Specialists such as breast, cardiology, or gastroenterology clinicians weigh in once a medical management plan takes shape.
What is a variant of uncertain significance (VUS) and what should I do about it?
A VUS is a gene change the lab spotted but cannot yet classify as benign or pathogenic. Treat it as inconclusive, skip enhanced screening or surgery until evidence accumulates, and check back with your genetics clinic every 12 to 24 months because roughly 7% to 15% of VUS results get reclassified within five years.
Will my genetic test results affect my insurance or employment?
GINA bars health insurers from using your results to deny coverage or raise premiums, and bars most employers from using them in hiring or promotion. Life, disability, and long-term care insurance fall outside GINA, and insurers in those markets can request your results during underwriting.
How do I share genetic test results with my family?
Ask your genetic counselor for a one-page family letter that names the gene, the variant, and a recommendation for targeted testing. Send it during a calm window rather than a family crisis, include the lab order form, and offer to answer questions by phone or video so relatives can act quickly.
